Loading quotes...
Forecast
| Buy |
Â
0 |
| Hold |
Â
2 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Conavi Medical increases revenue by 322% and significantly reduces annual loss per share
Conavi Medical reports revenue of CAD 9.12 million for the fiscal year ended 30 September 2025, up from CAD 2.16 million a year earlier, an increase of 322.22%. Loss per share narrowed to CAD -0.360 from CAD -7.080 in the prior year. The figures come from the quarterly/annual report filed on 29 December 2025. » More on finanzen.net
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 80.19k | 104.41% |
| Gross profit | -91.29k | 336.46% |
| Net profit | -3.9m | 76.03% |
| EBITDA | -3.77m | 101.14% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.51m |
Number of shares | 85.36m |
52-week high/low | €0.46 - €0.0631 |
| Dividends | No |
Beta | 0.54 |
P/E ratio | 13.22 |
PEG ratio | -0.02 |
P/B ratio | 18.74 |
P/S ratio | 5.13 |
Company profile
| Name | Conavi Medical Aktie |
| CEO | Thomas Looby |
| Employees | 4 |
